| 000 | 016070000a22003490004500 | ||
|---|---|---|---|
| 003 | EG-GICUC | ||
| 005 | 20250223025440.0 | ||
| 008 | 080904s2008 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GICUC _beng _cEG-GICUC |
||
| 041 | 0 | _aEng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.23.Ph.D.2008.Ra.C | ||
| 100 | 0 | _aRasha Mohammed Fahmi | |
| 245 | 1 | 0 |
_aComparative study of docetaxel versus paclitaxel in metastatic breast cancer patients / _cRasha Mohammed Fahmi ; Supervised Asmaa Ali Hassan , Mohammed Mousa , Mohammed Abdulla |
| 246 | 1 | 5 | _aدراسة مقارنة استخدام عقارى الدوسيتاكسيل والباكليتاكسيل فى حالات سرطان الثدى المنتشر |
| 260 |
_aCairo : _bRasha Mohammed Fahmi , _c2008 |
||
| 300 |
_a190P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty Of Medicine - Department Of Oncology | ||
| 520 | _aThe taxanes docetaxel and paclitaxel have significant clinical activity in metastatic breast cancer a number of clinical trials have evaluated the tolerability and efficacy of weekly taxane administration to optimize the benefit - torisk ratio in metastaic breast cancer | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aDocetaxel | |
| 653 | 4 | _aMetastaic breast cance | |
| 653 | 4 | _aPaclitaxel | |
| 700 | 0 |
_aAsmaa Ali Hassan , _eSupervisor |
|
| 700 | 0 |
_aMohammed Abdulla , _eSupervisor |
|
| 700 | 0 |
_aMohammed Mousa , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aEnas _eCataloger |
||
| 905 |
_aMustafa _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c13156 _d13156 |
||